With positive top-line phase III data from its EASE LID trial in hand, Adamas Pharmaceuticals Inc. will meet "as soon as is practical" with the FDA regarding a new drug application (NDA) for M2 channel-targeting ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia (LID) associated with Parkinson's disease (PD), CEO Gregory Went said.